Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation

Hitoshi Kawazoe, Yoshiharu Takiguchi, Tatsuya Inoue, Kazunori Yamaguchi, Hiroaki Tanaka, Masato Kaji, Shigeko Tsuji, Masaki Ninomiya, Noriyasu Fukuoka, Hiroaki Ohnishi, Toshihiko Ishida, Hitoshi Houchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Infections caused by multiple-drug-resistant Pseudomonas aeruginosa (MDRP) are a clinically significant problem. We reported here the effective use of combination therapy in a patient with infection caused by MDRP according to an interventional treatment strategy suggested by a pharmacist. The patient was a 70-year-old male who underwent allogeneic hematopoietic stem cell transplantation. On day 45 after transplant, MDRP was newly isolated from urine, but the diagnosis at that time was colonization. On day 61, the patient developed a fever (≥ 38.0°C). In addition, laboratory data showed that C-reactive protein (CRP) was also increased. At the medical team conference, the pharmacist proposed the following treatment strategy for this infection. Aztreonam and amikacin were intravenously administered at doses of 2 g/day and 800 mg/day, respectively. The subsequent clinical course was well controlled, but the infection recurred and was aggravated. Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. In conclusion, the combination therapy between aztreonam and amikacin, or ciprofloxacin may be clinically useful for severe infections of MDRP in compromised hosts.

Original languageEnglish
Pages (from-to)657-661
Number of pages5
JournalYakugaku Zasshi
Volume128
Issue number4
DOIs
Publication statusPublished - 2008 Apr 1
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Pseudomonas aeruginosa
Aztreonam
Infection
Pharmaceutical Preparations
Amikacin
Ciprofloxacin
Pharmacists
C-Reactive Protein
Fever
Therapeutics
Urine
Pseudomonas Infections
Transplants

Keywords

  • Combination therapy
  • Infection
  • Multiple-drug-resistant
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation. / Kawazoe, Hitoshi; Takiguchi, Yoshiharu; Inoue, Tatsuya; Yamaguchi, Kazunori; Tanaka, Hiroaki; Kaji, Masato; Tsuji, Shigeko; Ninomiya, Masaki; Fukuoka, Noriyasu; Ohnishi, Hiroaki; Ishida, Toshihiko; Houchi, Hitoshi.

In: Yakugaku Zasshi, Vol. 128, No. 4, 01.04.2008, p. 657-661.

Research output: Contribution to journalArticle

Kawazoe, H, Takiguchi, Y, Inoue, T, Yamaguchi, K, Tanaka, H, Kaji, M, Tsuji, S, Ninomiya, M, Fukuoka, N, Ohnishi, H, Ishida, T & Houchi, H 2008, 'Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation', Yakugaku Zasshi, vol. 128, no. 4, pp. 657-661. https://doi.org/10.1248/yakushi.128.657
Kawazoe, Hitoshi ; Takiguchi, Yoshiharu ; Inoue, Tatsuya ; Yamaguchi, Kazunori ; Tanaka, Hiroaki ; Kaji, Masato ; Tsuji, Shigeko ; Ninomiya, Masaki ; Fukuoka, Noriyasu ; Ohnishi, Hiroaki ; Ishida, Toshihiko ; Houchi, Hitoshi. / Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation. In: Yakugaku Zasshi. 2008 ; Vol. 128, No. 4. pp. 657-661.
@article{31f6b56f583e4ebcbc520568a1133670,
title = "Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation",
abstract = "Infections caused by multiple-drug-resistant Pseudomonas aeruginosa (MDRP) are a clinically significant problem. We reported here the effective use of combination therapy in a patient with infection caused by MDRP according to an interventional treatment strategy suggested by a pharmacist. The patient was a 70-year-old male who underwent allogeneic hematopoietic stem cell transplantation. On day 45 after transplant, MDRP was newly isolated from urine, but the diagnosis at that time was colonization. On day 61, the patient developed a fever (≥ 38.0°C). In addition, laboratory data showed that C-reactive protein (CRP) was also increased. At the medical team conference, the pharmacist proposed the following treatment strategy for this infection. Aztreonam and amikacin were intravenously administered at doses of 2 g/day and 800 mg/day, respectively. The subsequent clinical course was well controlled, but the infection recurred and was aggravated. Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. In conclusion, the combination therapy between aztreonam and amikacin, or ciprofloxacin may be clinically useful for severe infections of MDRP in compromised hosts.",
keywords = "Combination therapy, Infection, Multiple-drug-resistant, Pseudomonas aeruginosa",
author = "Hitoshi Kawazoe and Yoshiharu Takiguchi and Tatsuya Inoue and Kazunori Yamaguchi and Hiroaki Tanaka and Masato Kaji and Shigeko Tsuji and Masaki Ninomiya and Noriyasu Fukuoka and Hiroaki Ohnishi and Toshihiko Ishida and Hitoshi Houchi",
year = "2008",
month = "4",
day = "1",
doi = "10.1248/yakushi.128.657",
language = "English",
volume = "128",
pages = "657--661",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient underwent allogeneic hematopoietic stem cell transplantation

AU - Kawazoe, Hitoshi

AU - Takiguchi, Yoshiharu

AU - Inoue, Tatsuya

AU - Yamaguchi, Kazunori

AU - Tanaka, Hiroaki

AU - Kaji, Masato

AU - Tsuji, Shigeko

AU - Ninomiya, Masaki

AU - Fukuoka, Noriyasu

AU - Ohnishi, Hiroaki

AU - Ishida, Toshihiko

AU - Houchi, Hitoshi

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Infections caused by multiple-drug-resistant Pseudomonas aeruginosa (MDRP) are a clinically significant problem. We reported here the effective use of combination therapy in a patient with infection caused by MDRP according to an interventional treatment strategy suggested by a pharmacist. The patient was a 70-year-old male who underwent allogeneic hematopoietic stem cell transplantation. On day 45 after transplant, MDRP was newly isolated from urine, but the diagnosis at that time was colonization. On day 61, the patient developed a fever (≥ 38.0°C). In addition, laboratory data showed that C-reactive protein (CRP) was also increased. At the medical team conference, the pharmacist proposed the following treatment strategy for this infection. Aztreonam and amikacin were intravenously administered at doses of 2 g/day and 800 mg/day, respectively. The subsequent clinical course was well controlled, but the infection recurred and was aggravated. Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. In conclusion, the combination therapy between aztreonam and amikacin, or ciprofloxacin may be clinically useful for severe infections of MDRP in compromised hosts.

AB - Infections caused by multiple-drug-resistant Pseudomonas aeruginosa (MDRP) are a clinically significant problem. We reported here the effective use of combination therapy in a patient with infection caused by MDRP according to an interventional treatment strategy suggested by a pharmacist. The patient was a 70-year-old male who underwent allogeneic hematopoietic stem cell transplantation. On day 45 after transplant, MDRP was newly isolated from urine, but the diagnosis at that time was colonization. On day 61, the patient developed a fever (≥ 38.0°C). In addition, laboratory data showed that C-reactive protein (CRP) was also increased. At the medical team conference, the pharmacist proposed the following treatment strategy for this infection. Aztreonam and amikacin were intravenously administered at doses of 2 g/day and 800 mg/day, respectively. The subsequent clinical course was well controlled, but the infection recurred and was aggravated. Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. In conclusion, the combination therapy between aztreonam and amikacin, or ciprofloxacin may be clinically useful for severe infections of MDRP in compromised hosts.

KW - Combination therapy

KW - Infection

KW - Multiple-drug-resistant

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=41849108410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849108410&partnerID=8YFLogxK

U2 - 10.1248/yakushi.128.657

DO - 10.1248/yakushi.128.657

M3 - Article

C2 - 18379184

AN - SCOPUS:41849108410

VL - 128

SP - 657

EP - 661

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 4

ER -